We are live on ! Find out more

2,378 hedge funds and large institutions have $176B invested in Pfizer in 2019 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 926 increasing their positions, 1,102 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $1.74B | Put options by funds: $1.35B

23% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 75

2% more capital invested

Capital invested by funds: $173B → $176B (+$2.73B)

1% less funds holding

Funds holding: 2,3922,378 (-14)

0.68% less ownership

Funds ownership: 77.53%76.85% (-0.68%)

1% less funds holding in top 10

Funds holding in top 10: 202199 (-3)

16% less repeat investments, than reductions

Existing positions increased: 926 | Existing positions reduced: 1,102

Holders
2,378
Holders Change
-14
Holders Change %
-0.59%
% of All Funds
51.64%
Holding in Top 10
199
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-1.49%
% of All Funds
4.32%
New
92
Increased
926
Reduced
1,102
Closed
75
Calls
$1.74B
Puts
$1.35B
Net Calls
+$392M
Net Calls Change
+$151M
Name Holding Trade Value Shares
Change
Change in
Stake
TF
301
TIAA FSB
Florida
$30.4M -$3.96M -99,766 -12%
TU
302
TDAM USA
Ontario, Canada
$30.3M +$514K +12,946 +2%
OA
303
Oak Associates
Ohio
$30.1M +$564K +14,195 +2%
ASC
304
Atalanta Sosnoff Capital
New York
$30M -$7.73M -194,576 -21%
GF
305
Gabelli Funds
New York
$29.8M -$1M -25,296 -3%
NIM
306
Nexus Investment Management
Ontario, Canada
$29.6M +$585K +14,724 +2%
Fayez Sarofim & Co
307
Fayez Sarofim & Co
Texas
$29.1M -$4.82M -121,342 -15%
UH
308
Unigestion Holding
Switzerland
$29M +$3.52M +88,683 +14%
FP
309
Foundry Partners
Minnesota
$29M +$172K +4,321 +0.6%
PA
310
Pinnacle Associates
New York
$28.8M -$191K -4,798 -0.7%
NAM
311
Nissay Asset Management
Japan
$28.7M -$2.98M -75,170 -10%
SF
312
Synovus Financial
Georgia
$28.5M -$60.2K -1,515 -0.2%
SW
313
SVB Wealth
Massachusetts
$28.1M -$9.55M -240,598 -26%
AG
314
Advisor Group
Arizona
$27.9M +$517K +13,029 +2%
DCM
315
Donaldson Capital Management
Indiana
$27.8M +$103K +2,596 +0.4%
MIFH
316
Migdal Insurance & Financial Holdings
Israel
$27.8M -$7.72M -194,486 -22%
BAM
317
Berkshire Asset Management
Pennsylvania
$27.8M -$121K -3,036 -0.4%
HC
318
Henshaw Capital
Massachusetts
$27.7M +$5.04K +127 +0%
CIM
319
Corda Investment Management
Texas
$27.3M -$760K -19,139 -3%
FCM
320
Flinton Capital Management
Pennsylvania
$27.2M -$2.42M -60,884 -8%
CPSAC
321
Chas P. Smith & Associates (CPS)
Florida
$27.2M -$742K -18,674 -3%
TAF
322
Tredje AP-fonden
Sweden
$27.1M -$1.17M -29,516 -4%
ISL
323
Ingalls & Snyder LLC
New York
$26.8M +$45.9K +1,156 +0.2%
JAFL
324
Jay A. Fishman Ltd
Michigan
$26.8M -$1.76M -44,212 -6%
PP
325
Paloma Partners
Connecticut
$26.4M -$27.5M -693,574 -52%

PFE Hedge Fund Activity: Q2 2019 in Review

2,378 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2019, worth a combined $176B — up 1.6% from $173B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new PFE positions and 75 closed out — a net gain of 17 holders — while 926 added to existing stakes and 1,102 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $2.49B. The largest seller was BlackRock, cutting an estimated $829M.

  • 2,378 institutional investors held Pfizer (PFE) as of Q2 2019, down from 2,392 in Q1 2019.
  • Funds reported $176B of Pfizer stock for Q2 2019, up 1.6% quarter-over-quarter.
  • 92 funds opened new Pfizer positions in Q2 2019 and 75 closed out, a net change of +17 holders.
  • The largest Pfizer buyer in Q2 2019 was Wellington Management Group, an estimated $2.49B added.
  • The largest Pfizer seller in Q2 2019 was BlackRock, an estimated $829M sold.

Based on aggregated 13F filings for Q2 2019.